T
he coformulated medication consisting of 300 mg of tenofovir (TFV) disoproxil fumarate (TDF) and 200 mg of emtricitabine (FTC) is marketed as an antiviral combination tablet for treatment and preexposure prophylaxis (PrEP) of HIV infection (1) . TFV is a nucleotide analog, and its diphosphate anabolite (TFV-DP) has a structure similar to that of dATP; FTC is a nucleoside analog, and its trisphosphate (FTC-TP) has a structure similar to that of dCTP. TFV-DP and FTC-TP compete with dATP and dCTP (natural substrates) at the active site of HIV reverse transcriptase (RT), effectively inhibiting the biosynthesis of HIV genetic material. Once incorporated, they terminate the elongation of the HIV DNA chain due to the lack of a 3= hydroxyl group to incorporate the next component (2) . The ratio between drug concentration and the corresponding deoxynucleoside triphosphate (dNTP) affects the pharmacologic efficacy of TDF/FTC as a high ratio has been associated with greater antiviral activity (3, 4) .
It is well known that nucleos(t)ide analogs (NAs) can affect the endogenous dNTP pool, including dATP and dCTP, as well as dGTP, and TTP. NAs may compete with the host enzyme system for phosphorylation, as well as influence the complex dNTP pool metabolism pathways. For example, in vitro, TFV or its anabolites competitively inhibit creatine kinase (CK), phosphoglycerate kinase (PGK), and purine nucleoside phosphorylase (PNP) (5, 6) and upregulate 5= ecto-nucleotidases and 5= nucleotidase (NT) (7) . FTC and a similar deoxy-pyrimidine nucleoside analog, lamivudine (3TC), inhibit deoxycytidine kinase (dCK) (8, 9) . In addition, zidovudine (AZT), a thymidine analog, has been shown to inhibit thymidylate kinase 2 (TK2) (10, 11) . In HIV-infected patients, dATP increased during TDF/abacavir (ABC) dual therapy compared to the level with TDF monotherapy (12) and decreased during didanosine (ddI)-containing therapy relative to the level with TDF-containing therapy (13) . Taking these observations together, it is important to investigate the effects of TDF/FTC therapy on the endogenous dNTP pool in clinical settings.
The use of TDF/FTC for PrEP, as well as long-term treatment, requires a low toxicity profile for an acceptable risk-benefit balance (14) . TDF/FTC are generally safe and well tolerated (15) ; however, uncommon side effects have been reported, particularly in HIV-infected patients. For example, TDF is rarely associated with mitochondrial dysfunction in renal proximal tubule cells (16, 17) . Mitochondrial dysfunction can arise from an imbalance among purine and pyrimidine nucleotides (11, 18, 19) . Additionally, the TDF/ddI combination is correlated with a paradoxical CD4 T cell decline (20) that may be explained by PNP inhibition and subsequent apoptosis, which is associated with excessive in-tracellular dATP and dGTP (19, 21) . FTC moderately reduces cell proliferation in vitro (22) , which may be associated with imbalanced dNTP pools.
The characterization of the dNTP pool changes in patients receiving TDF/FTC enables the quantitation of the analog/dNTP ratio for pharmacologic efficacy and provides possible mechanisms of adverse effects. The goal of this pharmacodynamic study was to investigate the time profile of the dNTP pool, from baseline to TDF/FTC pharmacological intracellular steady state, in both HIV-positive and HIV-negative individuals.
MATERIALS AND METHODS
Participants and study design. The clinical protocol was approved by the institutional review broad (IRB) of the University of Colorado, and participants provided informed consent (Cell-PrEP trial; ClinicalTrials.gov identifier NCT01040091). HIV-negative adults were enrolled in an intensive clinical pharmacology study of daily coformulated TDF/FTC treatment for 30 days, followed by 30 days of washout. HIV-positive adults initiated TDF/FTC/efavirenz (EFV) treatment for 60 days (and beyond). All participants were tested for hepatitis B virus and were excluded if they were positive. Individuals were excluded if they were pregnant (or planning pregnancy), breastfeeding, had a body weight of less than 110 pounds, a modification of the diet in renal disease (MDRD) estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m 2 , a history of pathological bone fractures, an albuminuria creatinine ratio of more than 30, or a history of kidney disease. Participants' age, weight, sex, race, and body mass index (BMI) were recorded upon enrollment in the study. Peripheral blood mononuclear cell (PBMC) samples were taken at baseline and at 8 h postdose on days 1, 3, 7, 20, 30 , and 60 in all participants. The HIV-negative group had two additional visits on days 35 and 45 during the washout period. The study design is illustrated in Fig. 1 .
PBMC processing. A previously described method was used for PBMC processing (23) . Blood was drawn into a cell preparation tube (CPT). After the sample was mixed, the tube was spun at 1,800 ϫ g for 30 min at room temperature to separate plasma, PBMC, and red blood cells (RBC). The buffy layer (PBMCs) between the plasma and separation medium was collected into a 15-ml centrifuge tube. After RBC lysis to eliminate potential RBC contamination, the sample was washed with an equal volume of phosphate-buffered saline (PBS). The cell sample was then spun, and the cell pellet was resuspended in 5 ml of PBS for automated cell counting (Countess cell counter; Invitrogen/Thermo Fisher Scientific Corporation, Carlsbad, CA). Finally, the cells were spun again to pellet and lysed in 500 l of 70:30 methanol-water. The lysate was stored at Ϫ80°C until analysis.
The dNTP pool quantitation. The analytical method utilized a strong anion exchange isolation of mono-, di-, and triphosphates (MP, DP, and TP, respectively) from the intracellular matrix (23). The TP fraction was then dephosphorylated to the parent moiety (deoxynucleoside [dN]) yielding a molar equivalent to the original deoxynucleotide intracellular concentration. A reverse phase and weak cation exchange mixed-mode purification was then used for desaltation and concentration. Endogenous dNTP levels were then quantified using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method with an analytical range of 50 to 2,500 fmol/sample (24) . Statistical analysis. Data were natural log (ln) transformed for statistical analysis. The intracellular levels of the dNTPs (dATP, dCTP, dGTP, and TTP) were reported as geometric means and 95% confidence intervals (CIs). All statistical analyses were performed using SAS (version 9.4; SAS Institute, Inc., Cary, NC, USA).
To investigate the effects of HIV infection on the dNTP pool, the baseline data were analyzed. A Welch's t test was used to compare the dNTPs between HIV-negative and HIV-positive groups, and an F test was used to compare the difference of variances. Linear regression was performed to probe for the effects of subject variables at baseline using continuous variables such as age, weight, and BMI, while a Welch's t test and analysis of variance (ANOVA) were performed on categorical variables such as sex and race.
To evaluate the effects of TDF/FTC on the dNTP pool, longitudinal measurements from baseline to TDF/FTC pharmacological steady state in PBMCs (day 0 to 30) were used in both HIV-positive and HIV-negative groups. Time profiles of the dNTP pool were described and analyzed using mixed-model segmented linear regression (SAS Mixed procedure) (model equations are given in the supplemental material) (25) . The model estimated baseline, first slope, the change point (of two slopes), and the second slope. The change point was estimated by iteration (0 to 30 days, graduated by 0.05 in days), based on model goodness of fit (Akaike information criterion [AIC]) (26) . The variance structures (e.g., compound symmetry, heterogeneous compound symmetry, autoregressive model, and unknown structure) were assessed and selected also by the model goodness of fit. The differences between the change point versus baseline, day 30 versus baseline, and the change point versus day 30 were tested using SAS Estimate statements, and results were summarized as percentage change. Subject covariates were tested using a likelihood ratio test (LRT).
To evaluate the change of the dNTP pool during the washout period in the HIV-negative group, day 35, 45, and 60 data were compared to day 30 data, and day 60 data were also compared to the baseline level. A paired t test was used to compare the differences at two selected time points. To investigate the long-term treatment effects of TDF/FTC in the HIV-positive group, baseline and day 60 data were compared.
RESULTS

Study population.
A total of 40 participants were enrolled in the study. Among them, 21 were HIV-negative and 19 were HIVpositive patients. Thirty-four subjects completed all study visits, but six participants, two HIV-negative and four HIV-positive subjects (one female and five males), stopped early. One participant (HIV-positive) had a baseline sample but withdrew prior to any dosing visits, and the other five withdrew prior to the day 30 visit. One HIV-positive participant did not have a baseline sample but completed all visits. The study drug was generally well tolerated. The demographic characteristics of the study population are summarized in Table 1 .
Baseline characteristics of the dNTP pool. Data are presented in geometric means and 95% CIs in Table 2 . At baseline in PBMCs (n ϭ 39), it was observed that the HIV-negative group generally had higher dNTP pool levels than the HIV-positive group, with the exception of dATP levels. However, these differences were not statistically significant (P Ն 0.21). Statistically significant differences in variances were observed in all four dNTPs (P Յ 0.04), with higher variability in the HIV-negative group. No subject covariates (including age, weight, BMI, gender, and race) had a statistically significant effect associated with baseline dNTP levels (P Ն 0.17).
Changes in the dNTP pool on TDF/FTC therapy. tics are summarized in Table 3 . For all four models, a heterogeneous, compound symmetry (CSH) covariate structure best described the data. Throughout the study, no effects of subject covariates on intercepts or slopes (as interaction terms) were observed (P Ն 0.24).
Change in dCTP level. The change point of slopes for dCTP was day 1.55 with a decrease of 20% (95% CI, Ϫ28% to Ϫ11%; P Ͻ 0.0001) from baseline. Compared with the baseline, dCTP was decreased by 15% (95% CI, Ϫ23% to Ϫ6.4%; P ϭ 0.001) at day 30. After day 1.55, concentrations increased slightly between the change point and day 30 but was not statistically significant (5.8%; 95% CI, Ϫ2.4% to 15%; P ϭ 0.17).
Change in TTP level. The change point of slopes for TTP was reached at day 1.4 with a decrease of 37% (95% CI, Ϫ46% to Ϫ26%; P Ͻ 0.0001) from baseline. This 37% decrease remained at day 30 (95% CI, Ϫ47% to Ϫ27%; P ϭ 0.001). The change between day 1.4 and day 30 was not statistically significant (Ϫ1.2%; 95% CI, Ϫ15% to 14%; P ϭ 0.86).
Change in dATP level. The change point of slopes for dATP was reached at 2.9 days with a decrease of 14% (95% CI, Ϫ21% to Ϫ4.8%; P ϭ 0.003) from baseline. After that, although concentrations increased slightly, no statistically significant change between day 2.9 and day 30 was detected (6.5%; 95% CI, Ϫ2.3% to 16%; P ϭ 0.15). A decreasing trend was observed when day 30 was compared to the baseline value, with a reduction of 8.3% (95% CI, Ϫ17% to 0.80%; P ϭ 0.07).
Change in dGTP level. The change point of slopes for dGTP was reached at day 1.35 of therapy with a decrease of 19% (95% CI, Ϫ27% to Ϫ8.9%; P ϭ 0.0004) from baseline. Compared with the baseline, there was a decrease of 11% (95% CI, Ϫ20% to Ϫ0.67%; P ϭ 0.03) at day 30. A statistically significant increase was detected from the change point (day 1.35) to day 30, amounting to 9.6% (95% CI, 0.61% to 19%; P ϭ 0.04). Change in the dNTP pool in the washout period. The HIVnegative group was assigned to a 30-day washout period after 30 days of treatment. Compared to day 30 data, which represented the pharmacological steady state of TDF/FTC in PBMCs, deoxypyrimidine triphosphates increased throughout the washout period. A statistically significant increase of 20% (95% CI, 3.8% to 40%; P ϭ 0.02) in dCTP was observed 15 days after the initiation of the washout period. TTP increased by 83% (95% CI, 42% to 136%; P ϭ 0.0001) at day 5, 72% (95% CI, 34% to 121%; P ϭ 0.0004) at day 15, and 82% (95% CI, 33% to 149%; P ϭ 0.002) at day 30 of the washout period. However, for deoxy-purine triphosphates, statistically significant changes in dATP and dGTP were not observed (P Ն 0.38). Day 60 data compared to the baseline level was not statistically significant in dCTP (geometric means, 934 versus 1,038 fmol/10 6 cells; n ϭ 12; P ϭ 0.48) and TTP (geometric means, 496 versus 641 fmol/10 6 cells; n ϭ 11; P ϭ 0.14). However, statistically significant differences were observed for dATP and dGTP, with geometric means of 130 versus 181 fmol/ 10 6 cells (n ϭ 10; P ϭ 0.04) and 243 versus 343 fmol/10 6 cells (n ϭ 10; P ϭ 0.04). These results suggest that dCTP and TTP returned to baseline levels around 5 to 15 days after treatment discontinuation, while dATP and dGTP remained below the baseline level until at least day 30 of the washout period.
Change in the dNTP pool after 2 months of treatment. In the HIV-positive group, the day 60 results were compared to those at baseline. No statistically significant difference was observed in all four components (n ϭ 15; P Ն 0.28). The geometric means (95% CI) in femtomoles per million cells were 747 (631, 886) for dCTP, 354 (266, 470) for TTP, 159 (131, 193) for dATP, and 270 (226, 323) for dGTP, levels which were comparable to baseline levels (Table 1 ). This suggested that the dNTP pool recovered after treatment in HIV-infected patients.
DISCUSSION
In this study, we used PBMCs to investigate the effects of TDF/ FTC on the dNTP pool of HIV-positive and -negative adults. PBMCs include cells that are the major target of TDF/FTC (e.g., CD4 T cells). Also, these nucleated cells represent dNTP pool kinetics driven by enzymes such as PNP, which have high activity in PBMCs (6) .
At baseline, we observed generally lower dNTPs (except for dATP), but not a statistically significantly difference, in treat- ment-naive HIV-infected participants than in HIV-negative participants. However, the variance of the dNTP pool was higher in the HIV-negative group than in the HIV-positive group. Although a higher T-cell activation and cell proliferation might initially lead to dNTP pool upregulation (27, 28) , the pathological chronic cell activation during HIV infection (29) may induce anergy in T cells (30) . It is also reported that compensatory dNTP-consuming mechanisms associated with NTPDase-1 and SAMHD-1 are upregulated, especially in uncontrolled HIV-1 infection (31, 32) . These biological effects may have reduced the variability in dNTPs in HIV-infected participants. However, the small sample size (n ϭ 39) of our study limited the ability to probe possible effects of HIV infection and subject covariates on baseline dNTP pools. Future studies require a larger sample size to further address these questions. In HIV-infected patients, Hawkins et al. reported a lower dATP level with didanosine (ddI) than with other treatments, including TDF-including treatment (medians, 67.2 versus 186 fmol/ 10 6 cells; P ϭ 0.001), but could not exclude the possibility that TDF is also related to dATP reduction (13). Goicoechea et al. reported an increasing trend in dATP and dGTP with ABC/TDF dual therapy; however, in their 7-day monotherapy period, they observed a decreasing trend in dGTP (medians, 4,026 versus 2,464 fmol/10 6 cells; P ϭ 0.68) (12) . The study of Goicoechea et al. reported higher dATP and dGTP levels than the study by Hawkins et al. and the present study. In a macaque model, Durand-Gasselin et al. reported no change in dATP and dGTP levels from 2 to 24 h post-oral TDF and subcutaneous TFV treatment, but this study was limited by single-dose administration, a shorter observation period (Յ24 h), and the lack of a baseline observation (33) . Taken together, the present study represents a novel assessment of dNTP changes in PBMCs during TDF/FTC therapy. We observed that TDF/FTC therapy was associated with slight to moderate decreases in dNTP levels in both HIV-negative and HIV-positive individuals. A mixed-model segmented linear regression analysis was a useful approach to analyzing the dynamic changes in the dNTP pool during TDF/FTC treatment (34, 35) . In comparison to nonlinear regression models, the statistical analysis of the second slope from the segmented linear regression model enabled us to investigate the possible change points and return of the dNTPs during therapy (a statistically significant return was detected in dGTP). This work indicates that the dNTPs decrease within a few days (Ͻ3 days) of TDF/FTC initiation. However, the change point was estimated based on the model goodness of fit, and these temporal approximations were limited by sampling times. The detected effects of TDF/FTC on the dNTP pool were (largest to smallest) TTP Ͼ dCTP Ͼ dGTP Ͼ dATP, indicating that TDF/FTC had larger effects on deoxy-pyrimidine triphosphate compounds (dCTP and TTP) than deoxy-purines (dGTP and dATP). If these were driven by FTC, it could due to higher intracellular concentrations of FTC triphosphate (FTC-TP) than of TFV diphosphate (TFV-DP) (36) . We anticipate that lamivudine may induce similar effects, given the pharmacological similarity with emtricitabine (8, 9) . Studies are needed to assess on the effects of other NA such as abacavir and zidovudine.
In terms of potential mechanisms, the reduction of the dNTP pool could be explained by TFV-associated upregulation of the dephosphorylation enzymes 5=-ectonucleotidase and 5=-nucleotidase (7) . TFV also suppresses the ATP-generating enzymes CK and PGK (5) and indirectly inhibits kinases that use ATP as the phosphate donor, such as nucleoside diphosphate kinase (NDPK) (37) . Only in dGTP did we observe a statistically significant but minor return toward baseline values by day 30 after the change point was reached. Partial PNP inhibition by TFV phosphates might play a role in dGTP upregulation (38) , perhaps counteracting some of the reduction effects. However, the decreased dATP and dGTP levels observed in this study do not support PNP inhibition as a dominant effect of TDF, which would theoretically induce an increase of dATP and dGTP. FTC effects may be partly explained by the inhibition of dCK, which had also been shown for another deoxycytidine analog, 3TC (8, 14) .
During the washout period in the HIV-negative group, dCTP and TTP returned to baseline levels, while dGTP and dATP stayed slightly below the baseline levels. TFV-DP exhibits a much longer intracellular half-life than FTC-TP, and previous research in this cohort observed quantifiable intracellular TFV-DP concentrations at day 30 of the washout phase, whereas FTC-TP was below the limit of quantitation (39) . This is consistent with the suppression of dCTP and TTP being related to FTC-TP, while that of dATP and dGTP being related to TFV-DP. Future studies should investigate the individual effects of TDF and FTC on the dNTP pool in HIV-negative participants.
For long-term treatment in the HIV-positive group, day 60 data showed less reduction in the dNTP pool level than the plateau or the change point level, which indicates that, in our participants, the endogenous dNTP pool slowly returned to baseline with longterm treatment. We still need more information to understand other factors that may affect the dNTP pool in PBMCs after longterm treatment in HIV-infected patients, such as disease progression reversal, immune system restoration, and immune cell activation changes (14, 40) .
In conclusion, during TDF/FTC therapy, the dNTP pool slightly to moderately decreased within 3 days after the initiation of TDF/FTC therapy and generally remained below baseline at day 30. Potential clinical implications need to be evaluated in the future, including assessment of the analog/dNTP ratio over time, which influences the pharmacological efficacy of TDF/FTC (3, 4, 12) .
